KR20190077095A - 줄기 세포 유래 슈반 세포 - Google Patents

줄기 세포 유래 슈반 세포 Download PDF

Info

Publication number
KR20190077095A
KR20190077095A KR1020197017089A KR20197017089A KR20190077095A KR 20190077095 A KR20190077095 A KR 20190077095A KR 1020197017089 A KR1020197017089 A KR 1020197017089A KR 20197017089 A KR20197017089 A KR 20197017089A KR 20190077095 A KR20190077095 A KR 20190077095A
Authority
KR
South Korea
Prior art keywords
days
cell
population
cells
schwann cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197017089A
Other languages
English (en)
Korean (ko)
Inventor
로렌즈 스튜더
파라나크 파타히
Original Assignee
메모리얼 슬로안 케터링 캔서 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메모리얼 슬로안 케터링 캔서 센터 filed Critical 메모리얼 슬로안 케터링 캔서 센터
Publication of KR20190077095A publication Critical patent/KR20190077095A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062—General methods for three-dimensional culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
KR1020197017089A 2016-11-14 2017-11-14 줄기 세포 유래 슈반 세포 Ceased KR20190077095A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662421816P 2016-11-14 2016-11-14
US62/421,816 2016-11-14
PCT/US2017/061541 WO2018090002A1 (en) 2016-11-14 2017-11-14 Stem cell derived schwann cells

Publications (1)

Publication Number Publication Date
KR20190077095A true KR20190077095A (ko) 2019-07-02

Family

ID=62110088

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197017089A Ceased KR20190077095A (ko) 2016-11-14 2017-11-14 줄기 세포 유래 슈반 세포

Country Status (9)

Country Link
US (2) US20190331666A1 (https=)
EP (2) EP3538115A4 (https=)
JP (4) JP2019535263A (https=)
KR (1) KR20190077095A (https=)
CN (2) CN110249047A (https=)
AU (2) AU2017357076A1 (https=)
CA (2) CA3043226A1 (https=)
IL (2) IL266524A (https=)
WO (2) WO2018090006A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
US11511136B2 (en) * 2017-11-17 2022-11-29 The Research Foundation For The State University Of New York Method for treating damaged peripheral nerves using x-ray microbeam irradiation
CA3084259A1 (en) * 2017-12-04 2019-06-13 The Administrators Of The Tulane Educational Fund Cell systems using spheroids and methods of making and using the same
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
MX2021008797A (es) 2019-01-23 2022-01-31 Regeneron Pharma Tratamiento de afecciones oftalmicas con inhibidores de proteinas relacionadas a angiopoyetina 7 (angptl7).
CA3132136A1 (en) 2019-04-01 2020-10-08 Andrew Wasmuth Inhibitors of aldose reductase
JP2022531466A (ja) 2019-05-07 2022-07-06 ユニバーシティ オブ マイアミ 遺伝性ニューロパチーおよび関連障害の処置および検出
CN110157660A (zh) * 2019-06-10 2019-08-23 西安飞如生物科技有限公司 诱导成纤维细胞分泌抗菌肽的诱导培养基和方法、成纤维细胞及应用
JPWO2021166984A1 (https=) * 2020-02-20 2021-08-26
EP3929281A1 (en) 2020-06-24 2021-12-29 Fachhochschule Technikum Wien Cell construct comprising schwann cells or schwann cell-like cells and a biocompatible matrix
US11865134B2 (en) 2021-02-26 2024-01-09 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors
EP4355864A4 (en) * 2021-06-18 2025-04-23 Memorial Sloan Kettering Cancer Center Methods of generating sacral neural crest lineages and uses thereof
CA3265079A1 (en) * 2022-08-16 2024-02-22 The Regents Of The University Of California CELLULAR COMPOSITIONS AND THEIR METHODS OF USE
WO2025170529A1 (en) 2024-02-09 2025-08-14 Hedlund Eva A method for deriving a multipotent neuromesodermal progenitor cell and/or daughter lineages, and related compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023568A2 (en) * 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
CN101066472B (zh) * 2007-04-18 2010-05-19 中国人民解放军第二军医大学 组织工程化周围神经移植体及其制备方法
US8709805B2 (en) * 2009-08-07 2014-04-29 Kyoto University Canine iPS cells and method of producing same
WO2011046189A1 (ja) * 2009-10-15 2011-04-21 国立大学法人京都大学 神経変性疾患のモデル細胞、その製造方法及びその用途
CN102191217A (zh) * 2010-03-12 2011-09-21 上海市第一人民医院 一种诱导脐带间充质干细胞分化为类神经细胞的方法
DK3578988T3 (da) * 2010-05-25 2025-02-24 Memorial Sloan Kettering Cancer Center Fremgangsmåde til nociceptordifferentiering af humane embryonale stamceller og anvendelse heraf
BR112013008957A2 (pt) * 2010-10-15 2019-09-24 Univ Cornell composições e métodos para tratamento de doenças endócrinas, gastrointestinais ou autoimunes
EP3502236B1 (en) * 2011-02-18 2023-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
EP2614829A1 (en) * 2012-01-11 2013-07-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Mammalian neural plate border stem cells capable of forming neural tube and neural crest cell lineages including central and peripheral neurons
KR20160033703A (ko) * 2013-07-23 2016-03-28 에프. 호프만-라 로슈 아게 체세포로부터 신경 능선 세포로의 소분자 기반 전환
WO2015017523A1 (en) * 2013-07-30 2015-02-05 Waters Technologies Corporation Check valve having polymeric seat and poppet
GB201318126D0 (en) * 2013-10-14 2013-11-27 Univ Cardiff Neuronal Stem Cell Differentiation
AU2014352773B2 (en) 2013-11-21 2021-04-29 Memorial Sloan-Kettering Cancer Center Specification of functional cranial placode derivatives from human pluripotent stem cells
CN114657141B (zh) * 2014-09-12 2025-02-25 京都府公立大学法人 雪旺氏细胞及其制备方法
US20180140637A1 (en) * 2015-05-19 2018-05-24 Maya Sieber-Blum Epidermal neural crest stem cells as a source of schwann cells
KR101903458B1 (ko) * 2017-01-20 2018-10-02 한국생명공학연구원 슈반 세포 전구체 (Schwann cell precursor) 및 이로부터 분화된 슈반 세포 (Schwann cell)의 제조 방법

Also Published As

Publication number Publication date
CA3043223A1 (en) 2018-05-17
CA3043226A1 (en) 2018-05-17
US20190331666A1 (en) 2019-10-31
EP3538115A4 (en) 2020-04-22
EP3538115A1 (en) 2019-09-18
WO2018090002A1 (en) 2018-05-17
EP3538110A1 (en) 2019-09-18
CN110249047A (zh) 2019-09-17
CN110691601A (zh) 2020-01-14
JP2022059056A (ja) 2022-04-12
AU2017357076A1 (en) 2019-05-30
JP2019535263A (ja) 2019-12-12
US20190264173A1 (en) 2019-08-29
WO2018090006A1 (en) 2018-05-17
IL266554A (en) 2019-07-31
JP2019535265A (ja) 2019-12-12
JP2022090133A (ja) 2022-06-16
EP3538110A4 (en) 2020-04-22
IL266524A (en) 2019-07-31
AU2017357072A1 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
KR20190077095A (ko) 줄기 세포 유래 슈반 세포
JP7737787B2 (ja) 中脳ドーパミン（ｍＤＡ）ニューロンのｉｎ ｖｉｔｒｏ分化の方法
US11591567B2 (en) Specification of functional cranial placode derivatives from human pluripotent stem cells
US20230323294A1 (en) Differentiation of cortical neurons from human pluripotent stem cells
CN114650836B (zh) 中脑多巴胺神经元的产生和分离方法
JP2023156413A (ja) 背側化シグナル伝達物質又は腹側化シグナル伝達物質による錐体視細胞又は桿体視細胞の増加方法
JP7471084B2 (ja) 幹細胞由来星状細胞、作製方法および使用方法
JP7523885B2 (ja) 幹細胞由来外胚葉系統前駆体を分化する方法
JP2023075336A (ja) 幹細胞由来外胚葉系統前駆体を分化する方法
US12618044B2 (en) Specification of functional cranial placode derivatives from human pluripotent stem cells
EP4735585A1 (en) Enhancing neuronal differentiation of neural progenitor cells
Warrington Defining a small molecules differentiation cocktail for generation of dopaminergic neurons from Wharton’s jelly mesenchymal stem cells
CA2987617C (en) Methods of in vitro differentiation of midbrain dopamine (mda) neurons
Joy Directed differentiation of human pluripotent stem cells to telencephalic lateral ganglionic eminence progenitors using small molecules
Jaeger Midbrain dopaminergic neuron fate specification of pluripotent stem cells

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190613

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201116

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220828

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230601

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220828

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I